| Literature DB >> 4086245 |
L Pendyala, S Madajewicz, P J Creaven.
Abstract
Pharmacokinetics of CGP 15720A have been studied in patients receiving this drug in a short I.V. infusion during its phase I clinical trial. Plasma decay was biphasic with a mean t1/2 beta of 4.9 +/- 2.47h. The drug was cleared rapidly from plasma (7.02 +/- 5.95 L/h). Renal clearance (4.13 +/- 1.65 L/h) appears to be the major clearance pathway. The steady state volumes of distribution of the drug indicate limited tissue distribution for the drug. Studies with plasma and urine of patients receiving 14[C] GCP 15720A indicate that the drug is not metabolized. CGP 15720A could be measured in cerebrospinal fluid.Entities:
Mesh：
Substances：
Year: 1985 PMID： 4086245 DOI： 10.1007/BF00170761
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850